| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
|
|
|
|||||||
|
|||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 School of Biomedical Sciences, University of Ulster, Coleraine, Londonderry, United Kingdom
2 Department of Medical Physiology, The Panum Institute, University of Copenhagen, Copenhagen,, Denmark
* To whom correspondence should be addressed. E-mail: n.irwin{at}ulster.ac.uk.
The gut hormone gastric inhibitory polypeptide (GIP) plays a key role in glucose homeostasis and lipid metabolism. This study investigated the effects of administration of a stable and specific GIP-R antagonist, (Pro3)GIP in mice previously fed a high fat diet for 160 days to induce obesity and related diabetes. Daily i.p. injection of (Pro3)GIP over 50 days significantly decreased body weight compared with saline-treated controls with a modest increase in locomotor activity but no change of high fat diet intake. Plasma glucose, glycated haemoglobin and pancreatic insulin were restored to levels of chow-fed mice, and circulating triglyceride and cholesterol were significantly decreased. (Pro3)GIP treatment also significantly decreased circulating glucagon and corticosterone but concentrations of GLP-1, GIP, resistin and adiponectin were unchanged. Adipose tissue mass, adipocyte hypertrophy and deposition of triglyceride in liver and muscle were significantly decreased. These changes were accompanied by significant improvement of insulin sensitivity, meal tolerance and normalisation of glucose tolerance in (Pro3)GIP treated high fat fed mice. (Pro3)GIP concentrations peaked rapidly and remained elevated 24 h after injection. These data indicate that GIP-receptor antagonism action using (Pro3)GIP provides an effective means of countering obesity and related diabetes induced by consumption of high fat energy rich diet.
This article has been cited by other articles:
|
|
 |
|
  P D Cani, S Possemiers, T Van de Wiele, Y Guiot, A Everard, O Rottier, L Geurts, D Naslain, A Neyrinck, D M Lambert, et al. Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability Gut, August 1, 2009; 58(8): 1091 - 1103. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Musso, R. Gambino, G. Pacini, F. De Michieli, and M. Cassader Prolonged saturated fat-induced, glucose-dependent insulinotropic polypeptide elevation is associated with adipokine imbalance and liver injury in nonalcoholic steatohepatitis: dysregulated enteroadipocyte axis as a novel feature of fatty liver Am. J. Clinical Nutrition, February 1, 2009; 89(2): 558 - 567. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Kirino, Y. Sato, T. Kamimoto, K. Kawazoe, K. Minakuchi, and Y. Nakahori Interrelationship of dipeptidyl peptidase IV (DPP4) with the development of diabetes, dyslipidaemia and nephropathy: a streptozotocin-induced model using wild-type and DPP4-deficient rats J. Endocrinol., January 1, 2009; 200(1): 53 - 61. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Kim and J. M. Egan The Role of Incretins in Glucose Homeostasis and Diabetes Treatment Pharmacol. Rev., December 1, 2008; 60(4): 470 - 512. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Qi, J. T. Reed, G. Wang, S. Han, E. W. Englander, and G. H. Greeley Jr. Ghrelin secretion is not reduced by increased fat mass during diet-induced obesity Am J Physiol Regulatory Integrative Comp Physiol, August 1, 2008; 295(2): R429 - R435. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| Visit Other APS Journals Online |
